Non‐steroidal antiandrogen monotherapy vs LHRH agonists or surgical castration monotherapy: Gynaecomastia
Non‐steroidal antiandrogen monotherapy probably leads to higher gynaecomastia compared with LHRH agonists or surgical castration monotherapy (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Non‐steroidal antiandrogen monotherapy vs LHRH agonists or surgical castration monotherapy Gynaecomastia · men with advanced prostate cancer Non‐steroidal antiandrogen monotherapy probably leads to higher gynaecomastia compared with LHRH agonists or surgical castration monotherapy (moderate certainty). Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or… (2014) · Cochrane Headline outcomes only | RR 8.43 [3.19, 22.28] | 9 studies · 2774 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical castration monotherapy for… 2014 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.